Media coverage about Chimerix (NASDAQ:CMRX) has trended somewhat positive recently, according to Alpha One Sentiment. Alpha One, a service of Accern, identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real-time. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Chimerix earned a news impact score of 0.04 on Alpha One’s scale. Alpha One also gave media headlines about the biopharmaceutical company an impact score of 85 out of 100, meaning that recent news coverage is very likely to have an effect on the stock’s share price in the next several days.
Chimerix (NASDAQ:CMRX) traded down 1.610% during trading on Friday, reaching $5.805. The company’s stock had a trading volume of 35,852 shares. The firm’s 50-day moving average price is $6.12 and its 200 day moving average price is $5.26. The company’s market capitalization is $270.25 million. Chimerix has a 12-month low of $3.50 and a 12-month high of $6.64.
Chimerix (NASDAQ:CMRX) last announced its quarterly earnings data on Thursday, March 2nd. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.05. Chimerix had a negative return on equity of 32.09% and a negative net margin of 1,451.99%. The company had revenue of $1.98 million for the quarter, compared to analyst estimates of $0.89 million. On average, analysts predict that Chimerix will post ($1.67) earnings per share for the current fiscal year.
A number of equities analysts recently commented on the company. Zacks Investment Research downgraded Chimerix from a “buy” rating to a “hold” rating in a report on Thursday, February 16th. FBR & Co set a $8.00 target price on Chimerix and gave the company a “hold” rating in a report on Saturday, March 4th.
COPYRIGHT VIOLATION WARNING: This article was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://www.chaffeybreeze.com/2017/04/21/somewhat-favorable-news-coverage-very-likely-to-impact-chimerix-cmrx-share-price-updated.html.
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
Receive News & Ratings for Chimerix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc and related companies with MarketBeat.com's FREE daily email newsletter.